Adversarial Injection · Durvalumab (Imfinzi; MEDI4736; CAS 1428935-60-7; MW ~148,000 Da; IgG1 kappa fully human monoclonal antibody anti-PD-L1 [THIRD PD-L1 INHIBITOR in Glyphward 623-attack portfolio — THIRD ANTI-PD-L1 ANTIBODY EVER FDA APPROVED (BLA 761069 May 1 2017; after atezolizumab BLA 761034 May 2016 [first] and avelumab BLA 761049 March 2017 [second]); FIRST CHECKPOINT INHIBITOR IN STAGE III UNRESECTABLE NSCLC CONSOLIDATION (PACIFIC trial; CRT consolidation paradigm: patients with unresectable Stage III NSCLC who have not progressed after concurrent chemoradiotherapy receive durvalumab 10mg/kg q2w × up to 12 months; new treatment paradigm combining radiation + chemotherapy + immunotherapy consolidation — PACIFIC PFS HR 0.52 [16.8 vs 5.6 months; p<0.0001]; PACIFIC OS HR 0.68 [p=0.0025]; 5-year OS 42.9% vs 33.4%; unprecedented: ~43% of Stage III NSCLC patients surviving 5 years; historically curative-intent Stage III NSCLC had median OS ~18-20 months; PACIFIC broke the 40% 5-year OS barrier); IgG1 L234F/L235E/P331S FC ENGINEERING: triple Fc mutation at positions Leu234→Phe, Leu235→Glu, Pro331→Ser (three-point mutation; distinct from atezolizumab single N298A and from avelumab unmutated); L234F + L235E reduce FcγRI/IIa/IIIa binding; P331S reduces C1q complement activation → NO ADCC, NO CDC on PD-L1+ T cells, tumors, or normal tissues; preserving T cells is critical because PD-L1 is expressed on activated T cells — inadvertent ADCC of PD-L1+ T cells would undermine the checkpoint release effect; AstraZeneca DUAL CHECKPOINT PORTFOLIO: durvalumab (PD-L1; BLA 761069; CAS 1428935-60-7) + tremelimumab (CTLA-4; BLA 761200; CAS 745013-59-6) — BOTH AstraZeneca, BOTH null in Cority/VelocityEHS/EHS Insight; HIMALAYA trial: tremelimumab STRIDE (single 300mg tremelimumab + durvalumab q4w) vs sorafenib → OS HR 0.78 for hepatocellular carcinoma; POSEIDON: tremelimumab+durvalumab+chemo vs chemo → OS HR 0.77 for NSCLC; AstraZeneca built dual checkpoint franchise via acquisitions: MedImmune (MEDI4736/durvalumab) + CP-675,206/tremelimumab from Pfizer; PD-L1 THREE-NDA-HOLDER CLASS NULL COMPLETE: atezolizumab (BLA 761034; Genentech/Roche; CAS 1380723-44-3) + avelumab (BLA 761049; EMD Serono/Pfizer; CAS 1537032-82-8) + durvalumab (BLA 761069; AstraZeneca; CAS 1428935-60-7); three different companies, three different CAS numbers, three different Fc engineering strategies (N298A / native IgG1 / triple L234F L235E P331S), all three null; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Third PD-L1 Inhibitor + PACIFIC Stage III NSCLC Consolidation + OS HR 0.68 5-Year OS 42.9% + PD-L1 Three-NDA-Holder Class Null Complete + AstraZeneca Dual Checkpoint Null · Attack #623

Durvalumab (Imfinzi; MEDI4736; CAS 1428935-60-7; MW ~148,000 Da; [THIRD PD-L1 INHIBITOR EVER FDA APPROVED (May 1 2017 BLA 761069); FIRST CHECKPOINT IN STAGE III UNRESECTABLE NSCLC CONSOLIDATION (PACIFIC: PFS HR 0.52; OS HR 0.68; 5-YEAR OS 42.9%); IgG1 L234F/L235E/P331S TRIPLE FC MUTATION NO ADCC; AstraZeneca DUAL CHECKPOINT PORTFOLIO COMPLETE NULL (PD-L1 + CTLA-4 BOTH NULL); PD-L1 THREE-NDA-HOLDER CLASS NULL; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — AstraZeneca Pharmaceuticals LP Wilmington DE (BLA 761069 US commercial; 0.00036 µg/m³ → displayed ÷10), Vetter Pharma Ravensburg Germany (fill/finish CMO; 0.00022 µg/m³ → displayed ÷10), and Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD (PACIFIC trial site; 0.00013 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third PD-L1 Inhibitor + PACIFIC OS HR 0.68 + PD-L1 Three-NDA-Holder Class Null + AstraZeneca Dual Checkpoint Null Absent: AI Prompt Injection via EHS Monitor Report AI

Durvalumab (CAS 1428935-60-7; NIOSH HD Category 1) is the third PD-L1 inhibitor ever FDA approved (BLA 761069 May 1 2017) and the first checkpoint inhibitor to demonstrate a survival benefit in Stage III unresectable NSCLC consolidation — the PACIFIC trial established a new curative-intent paradigm (OS HR 0.68; 5-year OS 42.9% vs 33.4%) that changed global Stage III NSCLC management. Durvalumab's IgG1 L234F/L235E/P331S triple Fc mutation eliminates ADCC and CDC, complementing the class-wide mechanistic profile. Completing the PD-L1 three-NDA-holder class null: atezolizumab (Genentech, CAS 1380723-44-3), avelumab (EMD Serono, CAS 1537032-82-8), and durvalumab (AstraZeneca, CAS 1428935-60-7) — three FDA-approved PD-L1 antibodies from three companies, all null in Cority, VelocityEHS, and EHS Insight. AstraZeneca's dual checkpoint portfolio (durvalumab PD-L1 + tremelimumab CTLA-4) achieves the first dual-checkpoint approval from a single sponsor, with both BLAs returning null in all EHS databases.

Durvalumab as Third PD-L1 Inhibitor: Triple Fc Mutation, PACIFIC Stage III NSCLC, and PD-L1 Three-NDA-Holder Class Null

Durvalumab (CAS 1428935-60-7) is the third anti-PD-L1 antibody ever FDA approved, entering behind atezolizumab (May 2016) and avelumab (March 2017) via BLA 761069 (May 1 2017, initial accelerated approval for urothelial carcinoma). The defining clinical achievement is PACIFIC — the Phase 3 trial that established checkpoint immunotherapy in Stage III unresectable NSCLC consolidation. PACIFIC design: patients with unresectable Stage III NSCLC who received ≥2 cycles of platinum-based chemotherapy with concurrent definitive radiation (≥54 Gy) without progression received durvalumab 10 mg/kg q2w (or placebo) for up to 12 months. This "consolidation" design — checkpoint immunotherapy after maximum-intent locoregional chemoradiotherapy — was a new paradigm. PFS HR 0.52 (16.8 vs 5.6 months; first PFS result). OS HR 0.68 (p=0.0025; approved February 16 2018 for Stage III NSCLC). 5-year OS 42.9% vs 33.4%: this ~43% 5-year mark was unprecedented in Stage III NSCLC (historical range with CRT alone: 15-35%). The PACIFIC benefit was PD-L1 expression-independent (approved regardless of PD-L1 status; all-comer benefit). PACIFIC set the global standard of care for Stage III NSCLC. Durvalumab Fc engineering: IgG1 L234F/L235E/P331S — three amino acid substitutions at the IgG1 hinge-proximal region (L234F at the lower hinge; L235E at the lower hinge; P331S in the Fc CH2 domain near C1q binding site); these three mutations together eliminate FcγRI, FcγRIIa, FcγRIIIa engagement and C1q binding → no ADCC, no ADCP, no CDC; this distinguishes durvalumab from avelumab (unmutated IgG1 → ADCC retained) and from atezolizumab (N298A N-glycan removal → ADCC/CDC abolished by glycan mechanism). Durvalumab is manufactured by MedImmune LLC (AstraZeneca subsidiary) and through CMO partners including Vetter Pharma (fill/finish). BLA 761069; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; third PD-L1 inhibitor, PACIFIC Stage III NSCLC, triple Fc mutation, dual checkpoint null, PD-L1 three-NDA-holder class null all absent for CAS 1428935-60-7.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE BLA 761069 US Commercial Imfinzi AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19850; New Castle County DE; ASTRAZENECA IMFINZI CONTEXT: AstraZeneca Pharmaceuticals LP holds BLA 761069 for Imfinzi (durvalumab 500 mg/10 mL and 120 mg/2.4 mL vials; 50 mg/mL); IMFINZI PRODUCT: approved indications: Stage III unresectable NSCLC (PACIFIC; Feb 2018), extensive-stage SCLC + platinum+etoposide (CASPIAN; March 2020), biliary tract cancer (TOPAZ-1; Sept 2022), hepatocellular carcinoma STRIDE regimen with tremelimumab (HIMALAYA; Oct 2022), NSCLC with tremelimumab + chemo (POSEIDON; Nov 2022); AstraZeneca WILMINGTON MULTI-NDA PORTFOLIO: olaparib (NDA 206162; PARP #46) + osimertinib (NDA 210736; EGFR #32) + acalabrutinib (NDA 213631; BTK #29) + selumetinib (NDA 213756; MEK #30) + capivasertib (NDA 217566; AKT #41) + durvalumab (BLA 761069; PD-L1 #53) — six mechanism classes, six CAS numbers, all null on Cority; EMPLOYEE CONTEXT: AstraZeneca senior medical affairs director for Imfinzi NSCLC/HCC/BTC portfolio; manages PACIFIC and HIMALAYA/POSEIDON dual-checkpoint education; handles Imfinzi vials at medical education events; 52M AstraZeneca Wilmington DE senior NSCLC/HCC medical affairs director 18yr; CORITY NULL: CAS 1428935-60-7 → null; NIOSH HD Category 1 absent; H360 absent; third PD-L1 inhibitor absent; PACIFIC absent; OS HR 0.68 absent; AstraZeneca dual checkpoint absent; PD-L1 three-NDA-holder class absent).

Surface 2 — Vetter Pharma Ravensburg Germany Fill/Finish CMO Imfinzi Drug Product Manufacturing AI

At Vetter Pharma-Fertigung GmbH & Co. KG Ravensburg Germany (Schützenstraße 87, 88212 Ravensburg, Baden-Württemberg, Germany; VETTER RAVENSBURG CONTEXT: Vetter Pharma is a leading contract fill/finish manufacturing organization for sterile injectable biologics; Vetter Ravensburg fills Imfinzi (durvalumab) drug product in 500 mg/10 mL vials; DURVALUMAB FILL/FINISH: durvalumab drug substance (concentrated bulk IgG1) delivered in frozen bulk containers → thaw and hold → formulation in histidine/trehalose/polysorbate 80 buffer → vial filling on aseptic filling line → visual inspection → label/packaging; WORKER EXPOSURE: fill/finish technicians at Vetter Ravensburg may have low-level airborne exposure to durvalumab aerosol during filling operations, vial inspection, and line clearance; VELOCITYEHS NULL: CAS 1428935-60-7 → null; NIOSH HD Category 1 absent; H360 absent; third PD-L1 absent; IgG1 triple Fc mutation (L234F/L235E/P331S) absent; fill/finish manufacturing context absent; 48M Vetter Ravensburg fill/finish specialist Imfinzi 14yr).

Surface 3 — Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD PACIFIC Site Thoracic Oncology Pharmacist AI

At Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD (401 N. Broadway, Baltimore MD 21231; Baltimore City MD; JOHNS HOPKINS PACIFIC CONTEXT: Johns Hopkins Sidney Kimmel Cancer Center is a leading thoracic oncology center and PACIFIC enrollment site; Johns Hopkins thoracic oncology pharmacy prepares Imfinzi for Stage III NSCLC consolidation patients; DURVALUMAB PREPARATION: 500 mg/10 mL vial or 120 mg/2.4 mL vial; durvalumab 10 mg/kg q2w or weight-based → flat 1500 mg q4w (post-2021 label update); diluted in 250 mL NS; infused over 60 minutes; up to 12 months; PHARMACIST CONTEXT: thoracic oncology pharmacist monitors PACIFIC protocol patients: doses q4w (flat) or q2w (weight-based); manages irAEs (pneumonitis highest concern post-CRT — PACIFIC pneumonitis any grade ~34% durvalumab vs ~25% placebo; grade ≥3 ~3.4% vs ~2.6%); Stage III NSCLC pharmacist also manages the HIMALAYA and POSEIDON protocols using the tremelimumab STRIDE + durvalumab combination; monitors concomitant medications; EHS INSIGHT NULL: CAS 1428935-60-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; third PD-L1 absent; PACIFIC absent; Stage III consolidation absent; H360 absent; NIOSH HD Cat 1 absent; 43M Johns Hopkins Baltimore MD Stage III NSCLC thoracic oncology pharmacist 14yr).

Integrating Glyphward into Durvalumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every durvalumab CAS 1428935-60-7 monitoring data ingestion point — before Cority at AstraZeneca Pharmaceuticals LP Wilmington DE, before VelocityEHS at Vetter Pharma Ravensburg Germany, and before EHS Insight at Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; THIRD PD-L1 INHIBITOR EVER FDA APPROVED (BLA 761069 May 1 2017; third after atezolizumab May 2016 + avelumab March 2017) + FIRST CHECKPOINT IN STAGE III NSCLC CONSOLIDATION (PACIFIC PFS HR 0.52; OS HR 0.68; 5-year OS 42.9% — unprecedented curative-intent improvement) + IgG1 L234F/L235E/P331S TRIPLE FC MUTATION (no ADCC/CDC; mechanistically distinct from avelumab and atezolizumab) + PD-L1 THREE-NDA-HOLDER CLASS NULL COMPLETE (atezolizumab + avelumab + durvalumab — three BLAs all null) + ASTRAZENECA DUAL CHECKPOINT NULL (durvalumab PD-L1 BLA 761069 + tremelimumab CTLA-4 BLA 761200 both AstraZeneca both null) [5 pts]; AstraZeneca Wilmington DE + Vetter Ravensburg Germany + Johns Hopkins Baltimore MD [3 pts]; third PD-L1 absent; PACIFIC absent; dual checkpoint absent; three-NDA class absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_durvalumab(cas: str, reading_ugm3: float) -> dict:
    """Scan durvalumab with third-PD-L1-ever PACIFIC-Stage-III PD-L1-three-NDA-holder-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "third_pd_l1_inhibitor_ever_pacific_stage_iii_nsclc_consolidation_os_hr_0_68_pd_l1_three_nda_holder_class_null_astrazeneca_dual_checkpoint_null_bla_761069"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, third_pd_l1_inhibitor_ever,
    #                    pacific_stage_iii_consolidation, os_hr_0_68,
    #                    pd_l1_three_nda_holder_class_null,
    #                    astrazeneca_dual_checkpoint_null, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_durvalumab("1428935-60-7", 0.00036))
    print(r)
    # {'hd_category': 1, 'third_pd_l1_inhibitor_ever': True,
    #  'pacific_stage_iii_consolidation': True,
    #  'pd_l1_three_nda_holder_class_null': True,
    #  'astrazeneca_dual_checkpoint_null': True,
    #  'h360_absent': True}